PCRX
Price
$30.61
Change
-$0.21 (-0.68%)
Updated
May 20, 6:59 PM EST
72 days until earnings call
TEVA
Price
$16.81
Change
+$0.53 (+3.26%)
Updated
May 20, 6:59 PM EST
78 days until earnings call
Ad is loading...

PCRX vs TEVA

Header iconPCRX vs TEVA Comparison
Open Charts PCRX vs TEVABanner chart's image
Pacira BioSciences
Price$30.61
Change-$0.21 (-0.68%)
Volume$446.56K
CapitalizationN/A
Teva Pharmaceutical Industries
Price$16.81
Change+$0.53 (+3.26%)
Volume$3.25M
CapitalizationN/A
View a ticker or compare two or three
PCRX vs TEVA Comparison Chart

Loading...

PCRXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
TEVADaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
PCRX vs. TEVA commentary
May 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PCRX is a Hold and TEVA is a Hold.

COMPARISON
Comparison
May 21, 2024
Stock price -- (PCRX: $30.82 vs. TEVA: $16.29)
Brand notoriety: PCRX: Not notable vs. TEVA: Notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: PCRX: 69% vs. TEVA: 77%
Market capitalization -- PCRX: $1.36B vs. TEVA: $15.06B
PCRX [@Pharmaceuticals: Other] is valued at $1.36B. TEVA’s [@Pharmaceuticals: Other] market capitalization is $15.06B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $2.9B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PCRX’s FA Score shows that 0 FA rating(s) are green whileTEVA’s FA Score has 1 green FA rating(s).

  • PCRX’s FA Score: 0 green, 5 red.
  • TEVA’s FA Score: 1 green, 4 red.
According to our system of comparison, TEVA is a better buy in the long-term than PCRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PCRX’s TA Score shows that 5 TA indicator(s) are bullish while TEVA’s TA Score has 6 bullish TA indicator(s).

  • PCRX’s TA Score: 5 bullish, 5 bearish.
  • TEVA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, TEVA is a better buy in the short-term than PCRX.

Price Growth

PCRX (@Pharmaceuticals: Other) experienced а +4.76% price change this week, while TEVA (@Pharmaceuticals: Other) price change was +0.25% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.82%. For the same industry, the average monthly price growth was +6.48%, and the average quarterly price growth was +19331.34%.

Reported Earning Dates

PCRX is expected to report earnings on Jul 31, 2024.

TEVA is expected to report earnings on Aug 07, 2024.

Industries' Descriptions

@Pharmaceuticals: Other (+2.82% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
A.I.dvisor published
a Summary for PCRX with price predictions.
OPEN
A.I.dvisor published
a Summary for TEVA with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
TEVA($15.1B) has a higher market cap than PCRX($1.36B). PCRX has higher P/E ratio than TEVA: PCRX (32.74) vs TEVA (22.62). TEVA YTD gains are higher at: 56.035 vs. PCRX (-8.654). TEVA has higher annual earnings (EBITDA): 1.56B vs. PCRX (155M). TEVA has more cash in the bank: 3.23B vs. PCRX (279M). PCRX has less debt than TEVA: PCRX (586M) vs TEVA (20.2B). TEVA has higher revenues than PCRX: TEVA (15.8B) vs PCRX (675M).
PCRXTEVAPCRX / TEVA
Capitalization1.36B15.1B9%
EBITDA155M1.56B10%
Gain YTD-8.65456.035-15%
P/E Ratio32.7422.62145%
Revenue675M15.8B4%
Total Cash279M3.23B9%
Total Debt586M20.2B3%
FUNDAMENTALS RATINGS
PCRX vs TEVA: Fundamental Ratings
PCRX
TEVA
OUTLOOK RATING
1..100
1442
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
83
Overvalued
PROFIT vs RISK RATING
1..100
10082
SMR RATING
1..100
8492
PRICE GROWTH RATING
1..100
5050
P/E GROWTH RATING
1..100
9919
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PCRX's Valuation (64) in the Pharmaceuticals Other industry is in the same range as TEVA (83) in the Pharmaceuticals Generic industry. This means that PCRX’s stock grew similarly to TEVA’s over the last 12 months.

TEVA's Profit vs Risk Rating (82) in the Pharmaceuticals Generic industry is in the same range as PCRX (100) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew similarly to PCRX’s over the last 12 months.

PCRX's SMR Rating (84) in the Pharmaceuticals Other industry is in the same range as TEVA (92) in the Pharmaceuticals Generic industry. This means that PCRX’s stock grew similarly to TEVA’s over the last 12 months.

PCRX's Price Growth Rating (50) in the Pharmaceuticals Other industry is in the same range as TEVA (50) in the Pharmaceuticals Generic industry. This means that PCRX’s stock grew similarly to TEVA’s over the last 12 months.

TEVA's P/E Growth Rating (19) in the Pharmaceuticals Generic industry is significantly better than the same rating for PCRX (99) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew significantly faster than PCRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PCRXTEVA
RSI
ODDS (%)
Bearish Trend 1 day ago
70%
Bearish Trend 1 day ago
60%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
63%
MACD
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
70%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
65%
Bearish Trend 1 day ago
71%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 1 day ago
71%
Advances
ODDS (%)
Bullish Trend 7 days ago
67%
Bullish Trend 8 days ago
77%
Declines
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 4 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
73%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
71%
View a ticker or compare two or three
Ad is loading...
PCRXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
TEVADaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SLVRX32.850.14
+0.43%
Columbia Select Large Cap Value R
PLAYX18.550.03
+0.16%
PACE Large Co Growth Equity Y
VEVRX49.870.07
+0.14%
Victory Sycamore Established Value R6
CLQZX10.85N/A
N/A
Columbia Disciplined Growth Inst
OBGIX28.98-0.04
-0.14%
Oberweis Global Opportunities Instl

PCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PCRX has been loosely correlated with ELAN. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PCRX jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCRX
1D Price
Change %
PCRX100%
-2.19%
ELAN - PCRX
40%
Loosely correlated
+1.24%
TEVA - PCRX
35%
Loosely correlated
-0.06%
ACET - PCRX
27%
Poorly correlated
+1.91%
SNDL - PCRX
26%
Poorly correlated
-7.17%
NBIX - PCRX
25%
Poorly correlated
+0.27%
More

TEVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TEVA has been loosely correlated with ELAN. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if TEVA jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TEVA
1D Price
Change %
TEVA100%
-0.06%
ELAN - TEVA
41%
Loosely correlated
+1.24%
PCRX - TEVA
35%
Loosely correlated
-2.19%
VTRS - TEVA
33%
Poorly correlated
-0.36%
PAHC - TEVA
29%
Poorly correlated
+2.34%
PRGO - TEVA
27%
Poorly correlated
-0.90%
More